Neos Therapeutics (NEOS) Posts Wider-than-Expected Q2 Loss

Neos Therapeutics (NASDAQ: NEOS) reported Q2 EPS of ($7.76), $3.45 worse than the analyst estimate of ($4.31). Revenue for the quarter came in at $1.48 million versus the consensus estimate of $1.7 million.

For earnings history and earnings-related data on Neos Therapeutics (NEOS) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Equity Residential (EQR) Tops Q1 EPS by 44c; offers guidance
• Highwoods Properties (HIW) Tops Q1 EPS by 6c, provides guidance